HOME >> MEDICINE >> NEWS
NIH funds new brain imaging center at San Francisco VA Medical Center

A $2 million grant from the National Institutes of Health to use towards the purchase of the latest in brain-imaging equipment has been received by the San Francisco VA Medical Center.

The new high-field MRI/MR spectroscopy system will be the centerpiece of a new center for the imaging of neurodegenerative diseases, including Alzheimer's disease, epilepsy, post-traumatic stress disorder (PTSD), Gulf War syndrome and more, said Michael Weiner, MD, who will serve as the new center's director.

"This is going to be the only high-field system in the world that is focused exclusively on neurodegenerative diseases," said Weiner, who is director of the Magnetic Resonance Unit at San Francisco Veterans Affairs Medical Center and a professor of radiology, medicine, psychiatry and neurology at the University of California, San Francisco.

"This system will allow us to see smaller structures in the brain," Weiner said. The system measures different chemicals in the brain non-invasively and without the use of dyes or tracers. For example, it can measure the levels of glutamate, the neurotransmitter suspected of playing a role in Alzheimer's disease, amytropic lateral sclerosis (ALS or Lou Geherig's disease), and Parkinson's disease. "This is a unique resource," Weiner said.

The 4 Tesla high-field MRI/MR spectroscopy system is three times more powerful than the standard type of MRI in common use today. It will be used in particular for the early detection of Alzheimers--the most common disease of aging veterans and the elderly in general. The system will also be used to monitor the effectiveness of treatment of the disease.

In addition to patient treatment, the center will conduct research expected to advance the field significantly by testing the newest drug treatments developed specifically for Alzheimer's and other neurodegenerative disorders.

The $2 million grant comes from NIH's highly competitive Research Resources fund and w
'"/>

Contact: Camille Mojica Rey
cmrey@pubaff.ucsf.edu
415-221-4810 x5100
University of California - San Francisco
21-Nov-2002


Page: 1 2

Related medicine news :

1. Can you read my mind? W.M. Keck Foundation funds innovative brain research at Carnegie Mellon
2. Rices CNST awards Smalley/Curl funds for innovation
3. Entrepreneurism Center at UC San Diego funds commercialization of lung, shock, other devices
4. Federal funds given for regenerative medicine center
5. The NIH funds network to study drug-induced liver injury (DILIN)
6. NIH funds seven science education partnership awards
7. $25 million funds health promotion studies at UT School of Public Health
8. NIH funds project to help senior citizens access health care
9. NCCAM funds Developmental Centers for Research on Complementary and Alternative Medicine
10. NCCAM funds Centers of Excellence for Research on Complementary and Alternative Medicine
11. NIH funds two UCSD scientists to venture deep into human genome

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIH funds new brain imaging center San Francisco Medical Center

(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: